Human-specific polymorphic pseudogenization of SIGLEC12 protects against advanced cancer progression.
Siddiqui SS, Vaill M, Do R, Khan N, Verhagen AL, Zhang W, Lenz HJ, Johnson-Pais TL, Leach RJ, Fraser G, Wang C, Feng GS, Varki N, Varki A.
Siddiqui SS, et al. Among authors: vaill m.
FASEB Bioadv. 2020 Dec 8;3(2):69-82. doi: 10.1096/fba.2020-00092. eCollection 2021 Feb.
FASEB Bioadv. 2020.
PMID: 33615152
Free PMC article.